Bli medlem
Bli medlem

Du är här


aap: Sales in Q4/2015 at EUR 6.7 million and in FY/2015 at EUR 28.7 million

aap Implantate AG / aap: Sales in Q4/2015 at EUR 6.7 million and in FY/2015 at
EUR 28.7 million. Processed and transmitted by NASDAQ OMX Corporate
Solutions. The issuer is solely responsible for the content of this
Implantate AG (XETRA: AAQ.DE) generated sales of EUR 6.7 million (Q4/2014: EUR
8.6 million) in the fourth quarter of 2015 according to preliminary figures.
Sales in the full financial year 2015 totalled EUR 28.7 million (FY/2014: EUR
30.6 million) and were thus within the guidance of EUR 27.5 million to EUR
31.5 million announced in November 2015.

| In EUR million Q4/2015 Q4/2014 Change |
| Sales 6.7 8.6 -22% |
| Trauma 2.7 3.9 -31% |
| thereof LOQTEQ® 1.6 2.9 -45% |
| Biomaterials 3.7 3.7 0% |
| Projects 0.1 0.9 -90% |
| Other 0.2 0.1 >100% |

| In FY/2015 FY/2014 Change |
|EUR million |
| Sales 28.7 30.6 -6% |
| Trauma 11.0 12.2 -10% |
| thereof LOQTEQ® 6.8 8.2 -17% |
| Biomaterials 16.8 16.4 2% |
| Projects 0.3 1.2 -76% |
| Other 0.6 0.8 -20% |

In the trauma business,aap
Implantate AG realized sales of EUR 2.7 million (Q4/2014: EUR 3.9 million) in the fourth quarter of 2015. In the full year 2015 sales in the trauma business totalled EUR 11.0 million (FY/2014: EUR 12.2 million). The background to the decline in year-on-year trauma sales is, especially, the deteriorated economic framework conditions in several markets in the BRICS and SMIT states, which have been focal points of the company's growth strategy so far, and led to deviations from the sales development originally anticipated. At the same time the planned sales contribution from the US market has not yet materialised due to protracted administrative processes in hospitals.
The Management Board is confident the company will return to its growth path in the current financial year by means of the measures initiated, which are aimed primarily at intensifying sales activities in relatively more stable markets in Europe. In addition, the US market is to become a mainstay ofaap
Implantate AG's growth strategy in 2016.
In the biomaterials business,aap
Implantate AG generated sales of EUR 3.7 million in the fourth quarter of 2015 which were at the same level as in the previous year (Q4/2014: EUR 3.7 million). Overall, the biomaterials business registered again a satisfactory sales development in financial year 2015, with sales up slightly on the previous year to EUR 16.8 million (FY/2014: EUR 16.4 million). As part of the strategy to transformaap
Implantate AG into a focussed trauma company the necessary steps for a divestment ofaap
Biomaterials GmbH have been initiated already in the previous financial year. The company has put in place a structured process to take this forward and will be reporting on its progress.
In the silver coating technology area, approval-relevant work went ahead on schedule in the fourth quarter of 2015. On the basis of the current state of development and subject to the results of current consultations with the approval authoritiesaap
Implantate AG plans to submit the CE approval application for the silver coating technology by the end of January 2016.
The results contained in this press release are preliminary figures based on an initial analysis by the Management Board for the period ended on 31 December 2015 and are therefore subject to change.aap
Implantate AG plans to publish the final, audited results for the financial year 2015 on 30 March 2016.
In a further press release at the beginning of February 2016 the company will provide information about the outlook for the first quarter of 2016 and the full financial year 2016.

Implantate AG

aap Implantate AG is a globally operating medical device company headquartered
in Berlin, Germany. The company develops, manufactures and markets trauma and
biomaterials products for orthopedics. The trauma portfolio includes besides
the innovative anatomical plating system LOQTEQ® a wide range of cannulated
screws as well as standard plates and screws. In the biomaterials business
the company is specialized on bone cements and mixing systems. In
German-speaking countriesaap
Implantate AG directly sells its trauma products to hospitals, buying
syndicates and hospital groups while it uses a broad network of distributors
in more than 60 countries at the international level. In the biomaterials
business sales are handled via OEM and private label cooperations with
several selected international orthopedic and trauma companies.aap
Implantate AG's stock is listed in the Prime Standard segment of Frankfurt
Stock Exchange (XETRA: AAQ.DE). For more information, please visit, or download the Company's investor relations app from the Apple's
App Store or Google Play.
Forward-looking statement

This release may contain forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. Many
factors could cause the actual results, performance or achievements of aap to
be materially different from those that may be expressed or implied by such
statements. These factors include those discussed inaap
's public reports. Forward-looking statements therefore speak only as of the
date they are made.aap
does not assume any obligation to update the forward-looking statements
contained in this release or to conform them to future events or
For inquiries please contact:aap
Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin,

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail:


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.